Clinical Trials Logo

Clinical Trial Summary

The study is being conducted to evaluate the efficacy, safety and tolerability of SHR6390 in combination with nab-paclitaxel and gemcitabine in first-line treatment of subjects with advanced/metastatic pancreatic cancer.


Clinical Trial Description

This is an open-label, prospective, single-center, single-arm, Simon's two-stage design phase II study for unresectable advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) subjects treated with SHR6390 plus nab-paclitaxel and gemcitabine. In this research study, the main objectives include: 1. Evaluate objective response rate in patients with pancreatic cancer receiving SHR6390 plus nab-paclitaxel and gemcitabine. 2. Assess adverse side effects associated with the combination of SHR6390 with nab-paclitaxel and gemcitabine. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05185869
Study type Interventional
Source Ruijin Hospital
Contact Baiyong Shen, Ph.D&M.D
Phone 008613901943778
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date January 2022
Completion date October 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Not yet recruiting NCT05053555 - High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies N/A
Not yet recruiting NCT05052567 - CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma Phase 1/Phase 2
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Active, not recruiting NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
Suspended NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Not yet recruiting NCT04469504 - Preoperative Prehabilitation for Sarcopenic Patients Prior to Pancreatic Surgery for Cancer N/A
Not yet recruiting NCT05010226 - Focused Ultrasound for the Treatment of Pancreatic Cancer - an International Registry
Not yet recruiting NCT04899739 - Intraoperative Endoscopic Ultrasound for Pancreatic Cancer N/A
Recruiting NCT02954302 - Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy N/A
Active, not recruiting NCT02919787 - Nordic Pancreatic Cancer Trial (NorPACT) - 1 Phase 2/Phase 3
Active, not recruiting NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Completed NCT03054987 - Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction N/A
Completed NCT02358161 - Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer Phase 1/Phase 2